Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Immunotherapy of Primary Brain Tumors: Facts and Hopes.

Clinical cancer research : an official journal of the American Association for Cancer Research - 1 Nov 2018

Buerki Robin A, Chheda Zinal S, Okada Hideho

Abstract excerpt

The field of cancer immunotherapy has made exciting progress for some cancer types in recent years. However, recent failures of late-phase clinical trials evaluating checkpoint blockade in patients with glioblastoma (GBM) represent continued challenges for brain cancer immunotherapy. This is likely due to multiple factors including but not limited to marked genetic and antigenic heterogeneity, relatively low...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Immunomodulation
Share to Combined Modality Therapy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Antineoplastic Agents, Immunological

Share to Immunosuppressive Agents

Share to Immunotherapy

Share to Immunotherapy, Adoptive

Share to Oncolytic Virotherapy

Share to Oncolytic Viruses

Source

Open in PubMed Open full text

Identifiers

PMID: 29871908
DOI: 10.1158/1078-0432.CCR-17-2769
PMCID: PMC6214775

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Immunotherapy of Primary Brain Tumors: Facts and Hopes.PMID 29871908Read ↗

Clinical Trials Investigating Immune Checkpoint Blockade in Glioblastoma.Semantic proximity Read ↗

Immunotherapy: an emerging modality to checkmate brain metastasisSemantic proximity Read ↗

Deep immune profiling reveals targetable mechanisms of immune evasion in checkpoint blockade-refractory glioblastomaSemantic proximity Read ↗

Glioblastoma update: molecular biology, diagnosis, treatment, response assessment, and translational clinical trialsSemantic proximity Read ↗

Gene Targets of CAR-T Cell Therapy for GlioblastomaSemantic proximity Read ↗

Neoadjuvant Triplet Immune Checkpoint Blockade in Newly Diagnosed GlioblastomaSemantic proximity Read ↗

The glioblastoma multiforme tumor site promotes the commitment of tumor-infiltrating lymphocytes to the T H 17 lineage in humansSemantic proximity Read ↗

Oncolytic Viro-Immunotherapy: An Emerging Option in the Treatment of Gliomas.Semantic proximity Read ↗

Immune checkpoint blockade as a potential therapeutic target: surveying CNS malignancies.Semantic proximity Read ↗

Integrin blocking peptide reverses immunosuppression in experimental gliomas and improves anti-PD-1 therapy outcomeSemantic proximity Read ↗

Mutation-specific T cells for immunotherapy of gliomas.Semantic proximity Read ↗

Systemic viral vector vaccination induces brain resident memory T cells to drive anti-glioblastoma immunitySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.